Pharma Mar (PHMMF)
(Delayed Data from OTC)
$34.26 USD
0.00 (0.00%)
Updated Jul 2, 2024 01:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Pharma Mar falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 176 | 192 | 239 | 223 | 23 |
Receivables | 30 | 31 | 60 | 27 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 43 | 29 | 12 | 14 | 10 |
Other Current Assets | 25 | 38 | 38 | 16 | 10 |
Total Current Assets | 273 | 290 | 349 | 281 | 56 |
Net Property & Equipment | 47 | 33 | 32 | 25 | 25 |
Investments & Advances | 7 | 53 | 14 | 25 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 34 | 32 | 33 | 38 | 46 |
Intangibles | 2 | 3 | 4 | 4 | 7 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 369 | 414 | 436 | 377 | 140 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 34 | 32 | 35 | 27 | 22 |
Current Portion Long-Term Debt | 14 | 14 | 14 | 17 | 33 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 54 | 55 | 51 | 63 | 11 |
Total Current Liabilities | 104 | 103 | 102 | 108 | 68 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 24 | 47 | 81 | 106 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 29 | 27 | 40 | 43 | 59 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 159 | 179 | 225 | 260 | 131 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 12 | 12 | 13 | 13 | 12 |
Capital Surplus | 77 | 75 | 84 | 81 | 80 |
Retained Earnings | 154 | 165 | 143 | 48 | -78 |
Other Equity | 0 | 0 | 0 | 0 | -4 |
Treasury Stock | 34 | 17 | 30 | 25 | 2 |
Total Shareholder's Equity | 209 | 235 | 210 | 117 | 8 |
Total Liabilities & Shareholder's Equity | 369 | 414 | 436 | 377 | 140 |
Total Common Equity | 209 | 235 | 210 | 117 | 8 |
Shares Outstanding | 18.00 | 18.00 | 18.00 | 18.40 | 18.40 |
Book Value Per Share | 11.63 | 13.05 | 11.69 | 6.38 | 0.45 |
Fiscal Year End for Pharma Mar falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 176 | 190 | -99,999 |
Receivables | NA | NA | 30 | 33 | NA |
Notes Receivable | NA | NA | 0 | NA | NA |
Inventories | NA | NA | 43 | 38 | NA |
Other Current Assets | NA | NA | 25 | 23 | NA |
Total Current Assets | NA | NA | 273 | 284 | NA |
Net Property & Equipment | NA | NA | 47 | 43 | NA |
Investments & Advances | NA | NA | 7 | 13 | NA |
Other Non-Current Assets | NA | NA | 0 | NA | NA |
Deferred Charges | NA | NA | 34 | 34 | NA |
Intangibles | NA | NA | 2 | 2 | NA |
Deposits & Other Assets | NA | NA | 0 | NA | NA |
Total Assets | NA | NA | 369 | 380 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | NA | NA |
Accounts Payable | NA | NA | 34 | 23 | NA |
Current Portion Long-Term Debt | NA | NA | 14 | 14 | NA |
Current Portion Capital Leases | NA | NA | 0 | NA | NA |
Accrued Expenses | NA | NA | 0 | NA | NA |
Income Taxes Payable | NA | NA | 0 | NA | NA |
Other Current Liabilities | NA | NA | 54 | 55 | NA |
Total Current Liabilities | NA | NA | 104 | 94 | NA |
Mortgages | NA | NA | 0 | NA | NA |
Deferred Taxes/Income | NA | NA | 24 | 30 | NA |
Convertible Debt | NA | NA | 0 | NA | NA |
Long-Term Debt | NA | NA | 29 | 29 | NA |
Non-Current Capital Leases | NA | NA | 0 | NA | NA |
Other Non-Current Liabilities | NA | 0 | 0 | NA | |
Minority Interest (Liabilities) | NA | NA | 0 | NA | NA |
Total Liabilities | NA | NA | 159 | 156 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | NA | NA |
Common Stock (Par) | NA | NA | 12 | 12 | NA |
Capital Surplus | NA | NA | 77 | 78 | NA |
Retained Earnings | NA | NA | 154 | 162 | NA |
Other Equity | NA | NA | 0 | 0 | NA |
Treasury Stock | NA | NA | 34 | 27 | NA |
Total Shareholder's Equity | NA | NA | 209 | 224 | NA |
Total Liabilities & Shareholder's Equity | NA | NA | 369 | 380 | NA |
Total Common Equity | 0 | 0 | 209 | 100,223 | 0 |
Shares Outstanding | NA | NA | 18.00 | 18.00 | 18.00 |
Book Value Per Share | 0.00 | 0.00 | 11.63 | 5,567.97 | 0.00 |